CRISPR Therapeutics AG (CRSP) EBITDA Margin (2016 - 2026)
CRISPR Therapeutics AG's (CRSP) quarterly EBITDA Margin came in at 8895.27% in Q1 2026, up 656150.0% year-on-year from N/an in Q1 2025, and up 41.23% quarter-over-quarter from 15136.34% in Q4 2025.
CRISPR Therapeutics AG (CRSP) EBITDA Margin (2016 - 2026) Analysis & Trends
CRISPR Therapeutics AG has disclosed EBITDA Margin across 11 years of filings, most recently posting 8895.27% for Q1 2026.
- EBITDA Margin for Q1 2026 came in at 8895.27%, up 656150.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 14004.63% (down 1299608.0% YoY), and the FY2025 annual result was 16484.84%, down 1550311.0% from the prior year.
- EBITDA Margin came in at 8895.27% for Q1 2026 at CRISPR Therapeutics AG, up from 15136.34% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 48.73% in Q4 2023 to a low of 1732650.0% in Q4 2022.
- The 5-year median for EBITDA Margin is 15296.55% (2025), against an average of 137253.73%.
- Across the five-year window, EBITDA Margin tumbled 173152166 bps in 2022 and jumped 173269873 bps in 2023, its largest moves.
- CRISPR Therapeutics AG's EBITDA Margin stood at 1732650.0% in 2022, then surged by 100 bps to 48.73% in 2023, then tumbled by 365 bps to 128.98% in 2024, then plunged by 11635 bps to 15136.34% in 2025, then soared by 41 bps to 8895.27% in 2026.
- The last three EBITDA Margin figures came in at 8895.27% (Q1 2026), 15136.34% (Q4 2025), and 11866.82% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | CRISPR Therapeutics AG | 5.21 Bn | 2.76 Bn | - | -8,895.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8,895.27% |
| Dec 31, 2025 | -15,136.34% |
| Sep 30, 2025 | -11,866.82% |
| Jun 30, 2025 | -23,390.47% |
| Mar 31, 2025 | -15,456.76% |
| Dec 31, 2024 | -128.98% |
| Sep 30, 2024 | -12,042.86% |
| Jun 30, 2024 | -24,706.96% |
| Mar 31, 2024 | -23,820.63% |
| Dec 31, 2023 | 48.73% |
| Jun 30, 2023 | -110.37% |
| Mar 31, 2023 | -46.81% |
| Dec 31, 2022 | -1,732,650.00% |
| Sep 30, 2022 | -187,732.98% |
| Jun 30, 2022 | -119,799.37% |
| Mar 31, 2022 | -20,323.72% |
| Dec 31, 2021 | -1,128.34% |
| Sep 30, 2021 | -15,448.30% |
| Jun 30, 2021 | 84.27% |
| Mar 31, 2021 | -21,065.12% |